title: Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study.
abstract: To date, data on pituitary adenomas in MEN type 1 (MEN1) still have to be evaluated. We analyzed the data of a large series of 324 MEN1 patients from a French and Belgian multicenter study. Data on pituitary disease were compared with those from 110 non-MEN1 patients with pituitary adenomas, matched for age, year of diagnosis, and follow-up period. Genetic analysis of the MEN1 gene was performed in 197 of the MEN1 patients. In our MEN1 series, pituitary disease occurred in 136 of 324 (42%), less frequently than hyperparathyroidism (95%, P < 0.001) and endocrine enteropancreatic tumors (54%, P < 0.01). Mean age of onset of pituitary tumors was 38.0+/-15.3 yr (range, 12-83 yr). Pituitary disease was associated with hyperparathyroidism in 90% of cases, with enteropancreatic tumors in 47%, with adrenal tumors in 16%, and with thoracic neuroendocrine tumors in 4%. Pituitary disease was the initial lesion of MEN1 in 17% of all MEN1 patients. MEN1 pituitary adenomas were significantly more frequent in women than in men (50% vs. 31%, P < 0.001). Among the 136 pituitary adenomas, there were 85 prolactinomas and 12 GH-secreting, 6 ACTH-secreting, 13 cosecreting, and 20 nonsecreting tumors. Eighty-five percent of MEN1-related pituitary lesions were macroadenomas (vs. 42% in non-MEN1 patients, P < 0.001), including 32% of invasive cases. Among secreting adenomas, hormonal hypersecretion was normalized, after treatment, in only 42% (vs. 90% in non-MEN1 patients, P < 0.001), with a median follow-up of 11.4 yr. No correlation was found between the type of MEN1 germ-line mutation and the presence or absence of pituitary adenoma. Our study, based on a large group of MEN1 patients, shows that pituitary adenomas occur in 42% of the cases and are characterized by a larger size and a more aggressive presentation than without MEN1.
authors.affiliation: Department of Endocrinology, University Hospital, 21000 Dijon, France. bruno.verges@chu-dijon.fr
authors.forename: Bruno
authors.initials: B
authors.lastname: Vergès
authors.forename: Françoise
authors.initials: F
authors.lastname: Boureille
authors.forename: Pierre
authors.initials: P
authors.lastname: Goudet
authors.forename: Arnaud
authors.initials: A
authors.lastname: Murat
authors.forename: Albert
authors.initials: A
authors.lastname: Beckers
authors.forename: Geneviève
authors.initials: G
authors.lastname: Sassolas
authors.forename: Patrick
authors.initials: P
authors.lastname: Cougard
authors.forename: Béatrice
authors.initials: B
authors.lastname: Chambe
authors.forename: Corinne
authors.initials: C
authors.lastname: Montvernay
authors.forename: Alain
authors.initials: A
authors.lastname: Calender
mesh_terms: D000236:Adenoma / Q000150:complications* / Q000453:epidemiology / Q000503:physiopathology* / Q000628:therapy; D000328:Adult; D017677:Age Distribution; D004198:Disease Susceptibility; D005260:Female; D017353:Gene Deletion; D020022:Genetic Predisposition to Disease; D018095:Germ-Line Mutation; D006728:Hormones / Q000378:metabolism; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D018761:Multiple Endocrine Neoplasia Type 1 / Q000150:complications* / Q000235:genetics; D010911:Pituitary Neoplasms / Q000150:complications* / Q000453:epidemiology / Q000503:physiopathology* / Q000628:therapy; D012720:Severity of Illness Index; D017678:Sex Distribution; D016896:Treatment Outcome
chemical_list: D006728:Hormones